Monsanto Company (NYSE: MON) and ToolGen, Inc. (KONEX, 199800), a
biotechnology company specializing in genome editing, announced today
that the companies have reached a global licensing agreement for the use
of ToolGen’s CRISPR technology platform to develop agricultural products.

ToolGen is an early pioneer in gene editing research. The license
provides Monsanto with access to ToolGen’s comprehensive suite of CRISPR
intellectual property for use in plants. This agreement further expands
Monsanto’s broad portfolio of gene-editing tools that can be used to
develop improved and sustainable crops.

“We are excited to bring ToolGen’s CRISPR platform on board at Monsanto,
and are continuing to bolster and diversify our capabilities in this
field of research,” said Tom Adams, Ph.D., vice president of
biotechnology for Monsanto. “As a company we remain committed to the
development of safe, sustainable and high-quality crops, and look
forward to leveraging the CRISPR platform as we endeavor to meet the
needs of farmers while answering consumer demand for food options.”

In order to grow more using less, farmers need a variety of seed choices
to solve their local needs – like managing changing weather, fighting
plant disease and pests, and using crop inputs and natural resources
wisely. The companies noted that gene-editing technologies, like CRISPR,
offer agriculture researchers significant advantages over existing plant
breeding and biotechnology methods due to their versatility and
efficiency, and will allow Monsanto to provide farmers with solutions to
problems that have been previously unaddressed.

“We are pleased to announce our agreement with Monsanto, a global
agriculture leader, and look forward to working together to build new
and exciting opportunities in agriculture,” said Jongmoon Kim, chief
executive officer of ToolGen. “This agreement further validates our
platform and demonstrates the value that gene editing will hold for the
future of both agriculture and biotechnology.”

Additional terms of the agreement were not disclosed.

About Monsanto Company

Monsanto is committed to bringing a broad range of solutions to help
nourish our growing world. We produce seeds for fruits, vegetables and
key crops - such as corn, soybeans, and cotton - that help farmers have
better harvests while using water and other important resources more
efficiently. We work to find sustainable solutions for soil health, help
farmers use data to improve farming practices and conserve natural
resources, and provide crop protection products to minimize damage from
pests and disease. Through programs and partnerships, we collaborate
with farmers, researchers, nonprofit organizations, universities and
others to help tackle some of the world’s biggest challenges. To learn
more about Monsanto, our commitments and our more than 20,000 dedicated
employees, please visit
Follow our business on Twitter® at

About ToolGen, Inc.

ToolGen, Inc. is a biotechnology company focused on the development and
application of genome editing technologies. It creates, and holds
intellectual property rights for essential tools and technologies for
editing the genetic information in microbial, plant, animal, and human
cells. ToolGen’s mission is to translate the potential of our innovative
platform technology into transformative products for biomedicine and
agriculture. For more information, please visit

Cautionary Statements Regarding Forward-Looking Information:

Certain statements contained in this release are “forward-looking
statements,” such as statements concerning the company’s anticipated
financial results, current and future product performance, regulatory
approvals, business and financial plans and other non-historical facts,
as well as the pending transaction with Bayer Aktiengesellschaft
(“Bayer”). These statements are based on current expectations and
currently available information. However, since these statements are
based on factors that involve risks and uncertainties, the company’s
actual performance and results may differ materially from those
described or implied by such forward-looking statements. Factors that
could cause or contribute to such differences include, among others:
risks related to the pending transaction between the company and Bayer,
including the risk that the regulatory approvals required for the
transaction may not be obtained on the anticipated terms or time frame
or at all, the risk that the other conditions to the completion of the
transaction may not be satisfied, the risk that disruptions or
uncertainties related to the pending transaction could adversely affect
the company’s business, financial performance and/or relationships with
third parties, and the risk that certain contractual restrictions during
the pendency of the transaction could adversely affect the company’s
ability to pursue business opportunities or strategic transactions;
continued competition in seeds, traits and agricultural chemicals; the
company's exposure to various contingencies, including those related to
intellectual property protection, regulatory compliance and the speed
with which approvals are received, and public understanding and
acceptance of our biotechnology and other agricultural products; the
success of the company's research and development activities; the
outcomes of major lawsuits, including potential litigation related to
the pending transaction with Bayer; developments related to foreign
currencies and economies; fluctuations in commodity prices; compliance
with regulations affecting our manufacturing; the accuracy of the
company's estimates related to distribution inventory levels; the recent
increases in levels of indebtedness, continued availability of capital
and financing and rating agency actions; the company's ability to fund
its short-term financing needs and to obtain payment for the products
that it sells; the effect of weather conditions, natural disasters,
accidents, and security breaches, including cybersecurity incidents, on
the agriculture business or the company's facilities; and other risks
and factors detailed in the company's most recent periodic report to the
SEC. Undue reliance should not be placed on these forward-looking
statements, which are current only as of the date of this release. The
company disclaims any current intention or obligation to update any
forward-looking statements or any of the factors that may affect actual